FLINT, Mich., May 18, 2017 /PRNewswire/ -- Diplomat
Pharmacy, Inc. (NYSE: DPLO), is now dispensing
RYDAPT® (midostaurin), recently approved by the Food and
Drug Administration.
RYDAPT® (midostaurin) is approved to treat newly
diagnosed acute myeloid leukemia (AML) that is FLT3
mutation–positive, as detected by an FDA-approved test, in
combination with standard cytarabine and daunorubicin induction and
cytarabine consolidation.
RYDAPT® (midostaurin) inhibits multiple receptor
tyrosine kinases.
An oral therapy, RYDAPT® (midostaurin) is
administered twice daily for adults with FLT3 mutation–positive
AML.
The FDA also approved RYDAPT® (midostaurin) to treat
aggressive systemic mastocytosis, systemic mastocytosis with
associated hematological neoplasm, and mast cell leukemia.
RYDAPT® (midostaurin) is not indicated as a single-agent
induction therapy for patients with AML.
To learn more about Diplomat's oncology program, visit
diplomat.is/areas-of-excellence/oncology.
"We are excited about the recent approval of RYDAPT®
(midostaurin) to treat newly diagnosed FLT3-mutated AML patients.
It opens a new treatment strategy for these patients," said
Paul Urick, Diplomat president. "We
understand cancer treatments can be complex. Through our
coordinated care team, we are eager to provide patients this
encouraging new therapy option with our expertise and personal
support."
According to the American Cancer Society, AML is a form of
cancer in which the bone marrow makes irregular myeloblasts, red
blood cells, or platelets. Symptoms can include fatigue, recurrent
infections, and easy bruising. AML is most common in people older
than 45.
RYDAPT® (midostaurin) is manufactured by Novartis
Pharmaceutical Corporation. For full prescribing information, click
here.
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements give
current expectations or forecasts of future events or our future
financial or operating performance. The forward-looking
statements contained in this press release are based on
management's good-faith belief and reasonable judgment based on
current information. These statements are qualified by
important risks and uncertainties, many of which are beyond our
control, that could cause our actual results to differ materially
from those forecasted or indicated by such forward-looking
statements. For a discussion of such risks and uncertainties, you
should review Diplomat's filings with the Securities and Exchange
Commission, including "Risk Factors" in Diplomat's Annual Report on
Form 10-K for the year ended Dec. 31,
2016, and in subsequent reports filed with or furnished to
the Securities and Exchange Commission. Except as may be
required by any applicable laws, Diplomat assumes no obligation to
publicly update such forward-looking statements, which are made as
of the date hereof or the earlier date specified herein, whether as
a result of new information, future developments or otherwise.
About Diplomat
Diplomat (NYSE: DPLO) is the nation's largest independent
provider of specialty pharmacy services—helping patients and
providers in all 50 states. The company offers medication
management programs for people with complex chronic diseases and
delivers unique solutions for manufacturers, hospitals, payors,
providers, and more. Diplomat opened its doors in 1975 as a
neighborhood pharmacy with one essential tenet: "Take good care of
patients and the rest falls into place." Today, that tradition
continues—always focused on improving patient care and clinical
adherence. For more information, visit diplomat.is.
CONTACT:
Kali Lucas,
Public Relations Specialist
810.768.9580 | press@diplomat.is
Gary Rice, RPh, MS, MBA, CSP
Executive Vice President of Operations
810.768.9863 | grice@diplomat.is
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/diplomat-now-dispensing-rydapt-midostaurin-for-acute-myeloid-leukemia-300460388.html
SOURCE Diplomat Pharmacy, Inc.